Gene Therapy Product-MCO-010

BIOLOGICAL3 trials

Sponsors

Nanoscope Therapeutics Inc.

Conditions

Eye DiseasesEye Diseases, HereditaryRetinal DegenerationRetinal DiseasesRetinal DystrophiesRetinitisRetinitis PigmentosaStargardt Disease

Phase 2

Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

CompletedNCT04945772

Nanoscope Therapeutics Inc.Eye Diseases, Eye Diseases, Hereditary, Retinal Degeneration +4

Start: 2021-07-13End: 2024-01-18Updated: 2024-03-22

Unknown Phase

Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study

Active, not recruitingNCT06048185

Nanoscope Therapeutics Inc.Stargardt Disease

Start: 2023-10-19End: 2027-07-31Target: 6Updated: 2025-03-24

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

Active, not recruitingNCT06162585

Nanoscope Therapeutics Inc.Eye Diseases, Eye Diseases, Hereditary, Retinal Degeneration +4

Start: 2023-12-08End: 2027-09-30Target: 18Updated: 2025-03-24

Related Papers

A clinically viable approach to restoring visual function using optogenetic gene therapy.

2023-05-0915 citations